Table 3 Antimalarial treatments for patients who needed management with AL as defined by national guidelines

306 (66.4)

61.1–71.7

415 (56.2)

50.3–62.0

721 (60.1)

55.6–64.6

35 (7.6)

4.8–10.4

133 (18.0)

13.2–22.8

168 (14.0)

10.7–17.3

27 (5.9)

3.1–8.6

21 (2.8)

1.4–4.3

48 (4.0)

2.6–5.4

10 (2.2)

0.7–3.6

22 (3.0)

1.4–4.6

32 (2.7)

1.5–3.9

2 (0.4)

0–1.0

7 (1.0)

0–2.1

9 (0.8)

0–1.5

16 (3.5)

1.4–5.6

14 (1.9)

0.5–3.3

30 (2.5)

1.2–3.8

65 (14.1)

10.8–17.4

127 (17.2)

13.9–20.5

192 (16.0)

13.5–18.5

< 5 years (N = 428)

≥ 5 years (N = 644)

All patients (N = 1072)

n (%)

95% CI

n (%)

95% CI

n (%)

95% CI

297 (69.4)

64.2–74.6

388 (60.3)

54.2–66.3

685 (63.9)

59.5–68.3

22 (5.1)

2.8–7.5

95 (14.8)

10.1–19.4

117 (10.9)

8.0–13.9

22 (5.1)

2.4–7.9

16 (2.5)

1.0–4.0

38 (3.5)

2.2–4.9

9 (2.1)

0.6–3.6

16 (2.5)

0.8–4.2

25(2.3)

1.1–3.6

2 (0.5)

0–1.1

6 (0.9)

0–2.2

8 (0.8)

0–1.6

15 (3.5)

1.3–5.7

12 (1.9)

0.3–3.4

27 (2.5)

1.1–4.0

61 (14.3)

10.8–17.7

111 (17.2)

13.8–20.7

172 (16.0)

13.4–18.7